Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811776 | 0.94 | TDP1 (0.53) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL30596166 | 0.94 | CA12 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL14740858 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL14745412 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL31395837 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL499627 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL15969366 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL21070189 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL21070363 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL14744716 | 0.90 | CA1 (0.46) | CA1CA2CA12CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | YUAN YU (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119954715-A | Preparation method of doxylamine succinate | 金陵药业股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240391948-A1 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | SHAPERON INC. (KR) | 2024-11-28 | — | — | US | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| CN-116162071-B | Lipid compound, composition containing lipid compound, preparation method and application of lipid compound | 尧唐(上海)生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1241170-A2 | Pyrazolopyrimidine derivatives | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| CN-1280561-A | Amidocarboxylic acid derivatives | SANKYO CO (JP) | 2001-01-17 | — | — | CN | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-1019382-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998045275-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5710159-A | IMIDAZOLIN-2-YLAMINOPROPOXY)ISOXAZOL-5-CARBONYLAMINO-2 -BENZYLOXYCARBONYLAMINOPROPIONIC ACID AS ANTIINFLAMMATORY AGENTS, BONE DEGRADATION, TUMORS, METASTASES AND THROMBOSIS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0620824-A1 | PEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993014113-A1 | PEPTIDES WITH TACHYKININ ANTAGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | CA1 3545/4885CA2 2901/4885CA12 3366/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | CA1 4828/4885CA2 4084/4885CA12 4848/4885 |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | CA1 4518/4885CA2 3730/4885CA12 4295/4885 |
| US-20240391948-A1 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | TNF, IL1B, IL1A | CA1 4643/4885CA2 4749/4885CA12 4879/4885 |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | CA1 377/4885CA2 395/4885CA12 546/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | CA1 1237/4885CA2 3525/4885CA12 1736/4885 |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | SOS1, KRAS, SOS2 | CA1 2798/4885CA2 2906/4885CA12 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.